Resistance to SSAs may be defined as a failure to achieve biochemical control criteria (GH< 1.0 μg/L and a normal age-adjusted IGF-1) and increase in tumor size or tumor shrinkage <20% compared with baseline volume after at least 12 months of treatment with SSAs (45). The gene discussed is IGF1; the disease is neoplasm.